Dave Gennert, PhD
@davegennert.bsky.social
Genetics & bio nerd | science communications & writing | Science pubs @ Insilico Medicine | recovering journal editor | uses "wicked" as an adverb | posts & opinions my own
⭐ The first clinical validation of a drug designed by AI for a disease target discovered by AI
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
June 4, 2025 at 1:47 PM
⭐ The first clinical validation of a drug designed by AI for a disease target discovered by AI
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
In vivo, ~one week of ISM012-042 reduces disease activity, increased HIF1a & gut barrier target genes, restored gut barrier function, decreased inflam immune cells & cytokines in colon. Both prophylactic & post-colitis induction models.
December 12, 2024 at 4:53 PM
In vivo, ~one week of ISM012-042 reduces disease activity, increased HIF1a & gut barrier target genes, restored gut barrier function, decreased inflam immune cells & cytokines in colon. Both prophylactic & post-colitis induction models.
Our Chemistry42 generative #AI platform took over & designed novel molecule w/ low solubility, high clearance, moderate permeability to keep drug high in gut & low systemically to minimize off-target HIF1a (i.e., EPO & VEGF). 67-fold enrichment in gut vs plasma, in both healthy & colitis mice.
December 12, 2024 at 4:53 PM
Our Chemistry42 generative #AI platform took over & designed novel molecule w/ low solubility, high clearance, moderate permeability to keep drug high in gut & low systemically to minimize off-target HIF1a (i.e., EPO & VEGF). 67-fold enrichment in gut vs plasma, in both healthy & colitis mice.